SecBot SecBot
8-K ·Filed May 12, 2026

CCCC

C4 Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago SEC0001628280-26-033861
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The Q1 print is largely in-line with expectations for a clinical-stage biotech. Key catalysts to watch: EHA poster presentation (June 12), ASCO trial-in-progress poster (May 29-June 2), and initial ORR data from Phase 2 MOMENTUM in 2H 2027. The Roche collaboration provides non-dilutive capital and validates the DAC platform. The CFT8919 discontinuation outside China removes a pipeline asset but likely already discounted. Monitor cash burn rate and any future partnership milestones.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

C4 Therapeutics reported Q1 2026 revenue of $6.2M (down 14% YoY from $7.2M) and a net loss per share of -$0.20 (improved from -$0.37 YoY). The company highlighted clinical progress with cemsidomide (Phase 2 MOMENTUM enrolling, Phase 1b combo with elranatamab dosed) and a new Roche collaboration for degrader-antibody conjugates, but also announced it will not advance CFT8919 outside Greater China. Cash burn continues with $268.3M at quarter-end, providing runway to end of 2028.

Key Financial Metrics

EPS
−$0.20
est −$0.21 · +4.8%
Revenue
$6.2M
est $4.4M · +39.8% · -15.0% YoY
Rating
in line

Key Facts

  • Q1 2026 revenue $6.2M vs $7.2M YoY (-14%), driven by conclusion of Merck collaboration and prioritization of one KRAS project
  • Net loss per share -$0.20 vs -$0.37 YoY, improved on lower R&D spend ($24.6M vs $27.1M)
  • Cash, cash equivalents and marketable securities $268.3M as of March 31, 2026, down from $297.1M at Dec 31, 2025
  • Cash runway expected to fund operations to end of 2028
  • Phase 2 MOMENTUM trial of cemsidomide + dexamethasone in 4L+ multiple myeloma enrolling, enrollment completion expected Q1 2027
  • Phase 1b trial of cemsidomide + elranatamab initiated, first patient dosed March 2026
  • Additional Phase 1b combo trial with approved MM therapies expected to initiate in first half of 2027
  • C4T entered new collaboration with Roche in April 2026 for degrader-antibody conjugates, received $20M upfront payment in May 2026
  • Company decided not to advance CFT8919 (EGFR L858R degrader) outside Greater China
  • Received $2M milestone payment from Biogen for second degrader delivered to clinical development

Financial Impact

Revenue decline of ~14% YoY to $6.2M; net loss improved to -$25.1M from -$26.3M; cash burn ~$28.8M in Q1

revenuenet losscash position

Risk Factors

  • Revenue concentration on collaboration agreements with no approved products
  • Clinical trial execution risk for cemsidomide (Phase 2 MOMENTUM, Phase 1b combo)
  • Cash burn of ~$28.8M/quarter may require future capital raises before reaching profitability
  • CFT8919 discontinuation outside China narrows pipeline optionality
  • Dependence on partnership milestones for non-dilutive funding

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-033861
Document: maycorporatedeck_finalx5.htm0001628280-26-033861
Document: cccc-20260512.htm0001628280-26-033861
Document: 0001628280-26-033861-index-headers.html0001628280-26-033861
Document: 0001628280-26-033861-index.html0001628280-26-033861
Document: 0001628280-26-033861.txt0001628280-26-033861
8-K Data (Synthetic)0001628280-26-033861

Track record

19 reports on CCCC

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
  6. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  7. Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  8. Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  9. Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  10. Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026